Madrigal anticipates late 2027 MAESTRO-NASH OUTCOMES readout while planning 2,000+ patient MAESTRO-CSPH study
Open the sourceReported by Seeking Alpha, seekingalpha.com, 4 November 2026
45Impact 45 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.
Named in this story
Madrigal Pharmaceuticals, MAESTRO-NASH, MAESTRO-CSPH